Insider · CIK 0001957554
Kevin Balthaser
cfoofficer
Files at ACRS (Aclaris Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +1,100 | - | - | 90,960 | Mar 4, 2025 |
| Mar 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +2,375 | - | - | 93,335 | Mar 4, 2025 |
| Mar 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -727 | $1.99 | $1,447 | 92,608 | Mar 4, 2025 |
| Mar 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,100 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,375 | $0.00 | $0 | 2,375 | Mar 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +14,750 | - | - | 95,676 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -5,816 | $2.48 | $14k | 89,860 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -14,750 | $0.00 | $0 | 44,250 | Feb 4, 2025 |
| Feb 3, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +88,100 | $0.00 | $0 | 88,100 | Feb 4, 2025 |
| Feb 3, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +308,200 | $0.00 | $0 | 308,200 | Feb 4, 2025 |
| Dec 31, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +73,750 | - | - | 98,447 | Jan 3, 2025 |
| Dec 31, 2024 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -30,732 | $2.48 | $76k | 67,715 | Jan 3, 2025 |
| Jan 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +7,500 | - | - | 75,215 | Jan 3, 2025 |
| Jan 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -2,430 | $2.48 | $6,026 | 72,785 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +13,200 | - | - | 85,985 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -5,059 | $2.48 | $13k | 80,926 | Jan 3, 2025 |
| Dec 31, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -73,750 | $0.00 | $0 | 73,750 | Jan 3, 2025 |
| Jan 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -7,500 | $0.00 | $0 | 15,000 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +40,000 | $0.00 | $0 | 40,000 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -13,200 | $0.00 | $0 | 26,800 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.